Ligand Pharmaceuticals Incorporated acquires Pfenex Inc. (2020)

Deal facts

Buyer: Ligand Pharmaceuticals Incorporated
Target: Pfenex Inc.
Deal value: Not disclosed
Announced: 10 August 2020
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash, earn-out

Sources

SEC_EDGAR_8K

What we know

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

1 Oct 2020CompletedClosed
Ligand Pharmaceuticals Incorporated completes acquisition of Pfenex Inc.
Item 2.01 Completion of Acquisition or Disposition of Assets. On October 1, 2020, Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Ligand”), completed the previously announced acquisition of Pfenex Inc., a Delaware corporation (“Pfenex”), pursuant to the Agreement and Plan of Merger (the “Merger Agreement”), dated as of August 10, 2020, by and among Ligand, Pfenex and Pelican Acquisit
Source

OpinionExit Mode editorial

We see a clear signal in the transaction where Ligand Pharmaceuticals Incorporated acquired Pfenex Inc. to take the target private. Announced on 10 August 2020, this deal moved a US healthcare firm from public markets into private ownership. The structure relies on a mix of cash and an earn-out. This specific combination often reflects a buyer who wants immediate control but needs the seller to prove future performance before releasing the full price. It is a common mechanic when the acquirer sees value that the market currently underestimates but requires validation over time.

For the SME founder reading this, the choice of an earn-out introduces a distinct commercial risk. It shifts the burden of value creation onto the post-close period. If the business does not hit the agreed targets, the final consideration drops. This is not merely a pricing detail; it is a change-of-control covenant that dictates your operational freedom for years. In the healthcare sector, where regulatory timelines and clinical outcomes drive value, tying a portion of the sale to future milestones can be precarious. The buyer assumes the asset, yet the seller remains financially exposed until the earn-out conditions are satisfied.

The going-private nature of this deal also suggests a desire to escape the short-term pressures of public reporting. Ligand likely sought the flexibility to restructure or integrate Pfenex without quarterly scrutiny. While this offers strategic breathing room, it removes the liquidity event that many founders expect. The deal status is now completed, meaning the terms were accepted and the transition executed. This outcome highlights that even in a sector as stable as healthcare, the path to exit often involves trade-offs between immediate cash and future potential.

You must scrutinise the earn-out triggers in your own data room this week. Do not accept vague language regarding performance metrics. Define the specific clinical or commercial milestones that unlock the deferred payment and ensure they are within your team's direct control. If the targets rely on external regulatory approvals or market shifts you cannot influence, the deal value is illusory. Demand clarity on the measurement period and the dispute resolution mechanism before signing.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2020 deals More going private deals More from Ligand Pharmaceuticals Incorporated All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

13 October 2026Firm intentionHealthcare

ArcheNova Technology Co., Ltd to acquire ArcheNova Biotech Corp.

ArcheNova Technology Co., Ltd has agreed to acquire ArcheNova Biotech Corp. in a transaction valued at two billion US dollars. The deal, announced on 13 October 2026, in…

Buyer: ArcheNova Technology Co., Ltd
Target: ArcheNova Biotech Corp.
Deal value: USD 2,000,000,000
Deal type: going private

Read deal Healthcare deals going private deals Cayman Islands deals

5 October 2026Firm intentionHealthcare

Onyx Bidco LLC to acquire Option Care Health, Inc.

Onyx Bidco LLC has agreed to acquire Option Care Health, Inc. in a cash transaction. The deal, announced on 5 October 2026, involves the US-based buyer purchasing the US…

Buyer: Onyx Bidco LLC
Target: Option Care Health, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

28 September 2026Firm intentionHealthcare

Lifecore Inc. to acquire Lifecore Biomedical, Inc.

Lifecore Inc. has agreed to acquire Lifecore Biomedical, Inc. in a transaction designed to take the healthcare company private. The deal was announced on 28 September 20…

Buyer: Lifecore Inc.
Target: Lifecore Biomedical, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

7 September 2026Firm intentionHealthcare

TULIP UK BIDCO LIMITED to acquire Spire Healthcare Group plc

TULIP UK BIDCO LIMITED has agreed to acquire Spire Healthcare Group plc in a going private transaction valued at approximately GBP 1.0265 billion. The deal structure inv…

Buyer: TULIP UK BIDCO LIMITED
Target: Spire Healthcare Group plc
Deal value: GBP 1,026,500,000
Deal type: going private

Read deal Healthcare deals going private deals United Kingdom deals

3 August 2026In reviewHealthcare

Curium US Holdings LLC to acquire Lantheus Holdings, Inc.

Curium US Holdings LLC has agreed to acquire Lantheus Holdings, Inc. in a transaction designed to take the healthcare company private. The deal was announced on 3 August…

Buyer: Curium US Holdings LLC
Target: Lantheus Holdings, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

Buyer history